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Highlights
• This is the first Canadian study to 
investigate the association between 
bisphenol A (BPA) and adiposity 
measures.
• A higher level of urinary BPA is 
associated with greater odds of 
being obese among Canadian adults 
18 to 79 years of age. 
• Urinary BPA concentration is also 
positively associated with continu-
ous measures of adiposity, includ-
ing body mass index and waist 
circumference.
• Prospective studies with repeated 
measures are needed to address 
temporality and improve exposure 
classification.
prevalence and increasing production of 
synthetic chemicals, including bisphenol 
A (BPA).5 BPA is an endocrine-disrupting 
chemical commonly found in food and 
beverages stored in polycarbonate plastic 
and epoxy resin containers.6 The primary 
route of exposure to BPA is through 
dietary intake, although dermal exposure 
can also occur from skin contact with 
thermal paper (e.g. receipts, tickets).6 
More than 90% of Canadians7 and 
Americans8 have detectable levels of BPA 
in their urine, indicating widespread expo-
sure in human populations.
In vitro studies have shown that BPA 
enhances adipocyte cell differentiation, 
leading to excess fat accumulation.9 
Rodent studies have also found BPA expo-
sure to increase adipose tissue mass and 
promote weight gain.10 More recently, 
Abstract
Introduction: Exposure to bisphenol A (BPA) has been shown to affect lipid metabo-
lism and promote weight gain in animal studies. Recent epidemiological studies also 
support a link between BPA and obesity in human populations, although many were 
limited to a single adiposity measure or have not considered potential confounding by 
dietary factors. The purpose of this study is to examine associations between urinary 
BPA and adiposity measures in a nationally representative sample of Canadian adults.
Methods: We performed analyses using biomonitoring and directly measured anthropo-
metric data from 4733 adults aged 18 to 79 years in the Canadian Health Measures 
Survey (2007–2011). We used multinomial and binary logistic regression models to esti-
mate associations of urinary BPA with body mass index (BMI) categories (overweight 
vs. under/normal weight; obesity vs. under/normal weight) and elevated waist circum-
ference (males: ≥ 102 cm; females: ≥ 88 cm), respectively, while controlling for potential 
confounders. Linear regression analyses were also performed to assess associations 
between urinary BPA and continuous BMI and waist circumference measures. 
Results: Urinary BPA was positively associated with BMI-defined obesity, with an odds 
ratio of 1.54 (95% confidence interval [CI]: 1.002–2.37) in the highest (vs. lowest) BPA 
quartile (test for trend, p = .041). Urinary BPA was not associated with elevated waist 
circumference defined using standard cut-offs. Additionally, each natural-log unit 
increase in urinary BPA concentration was associated with a 0.33 kg/m2 (95% CI: 0.10–
0.57) increase in BMI and a 1.00 cm (95% CI: 0.34–1.65) increase in waist 
circumference.
Conclusion: Our study contributes to the growing body of evidence that BPA is posi-
tively associated with obesity. Prospective studies with repeated measures are needed 
to address temporality and improve exposure classification.
Keywords: bisphenol A, endocrine disruptors, obesity, body mass index, waist 
circumference, biomonitoring, Canadian Health Measures Survey
important factors contributing to the obe-
sity epidemic.4
Given the dramatic increase in obesity 
over the past several decades, additional 
hypotheses are being explored to identify 
other potentially modifiable risk factors 
beyond the energy imbalance equation. 
Ecological studies initially reported a 
correlation between increasing obesity 
Introduction
Obesity is a growing epidemic worldwide 
and is expected to exceed smoking as a 
leading contributor to the burden of 
chronic disease.1,2 In Canada, one in four 
adults is obese.3 Excess consumption of 
energy-dense foods, inadequate physical 
activity, and increased sedentary behav-
iour have been identified as the most 
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evidence of a relationship between BPA 
and obesity in humans has emerged but is 
limited to a small number of populations. 
To date, epidemiological studies in the 
USA,11,12 China,13 and Korea14,15 have 
reported positive associations between 
BPA and adiposity measures in adults. 
Moreover, as an estrogen-like compound, 
BPA has been shown to affect males and 
females differently in animal models,16 
although evidence of sex differences in 
the association between BPA and obesity 
in humans is limited.
Since 2007, the Canadian Health Measures 
Survey (CHMS) has been collecting bio-
monitoring data and anthropometric mea-
sures from a nationally representative 
sample of Canadians. Given widespread 
exposure to BPA in Canada and existing 
evidence supporting the link between BPA 
and obesity, we evaluated associations 
between urinary BPA and measures of adi-
posity in adults aged 18 to 79 years using 
CHMS data, overall and by sex.
Methods
Data source and study population
This study utilized data from cycles 1 
(2007–2009) and 2 (2009–2011) of the 
CHMS. Details of the CHMS have been 
described elsewhere.17,18 Briefly, the CHMS 
is an ongoing cross-sectional survey that 
uses a multistage stratified sampling 
design to collect nationally representative 
data of the Canadian household popula-
tion, excluding persons living on reserves 
or other Aboriginal settlements, full-time 
members of the Canadian Forces, and resi-
dents of institutions and certain remote 
regions. Cycle 1 collected data from 5604 
respondents aged 6 to 79 years at 15 sites 
across Canada; cycle 2 collected data from 
6395 respondents aged 3 to 79 years at 18 
sites. The sample for each cycle repre-
sented approximately 96% of the Canadian 
population in the target age range. 
The CHMS consists of an in-home house-
hold interview capturing sociodemo-
graphic, lifestyle, and health characteristics, 
followed by a mobile examination centre 
(MEC) visit for direct physical measures, 
including anthropometric measurements 
and collection of blood and urine samples. 
Written informed consent was obtained 
from each respondent. Protocols were 
reviewed and approved by Health Canada 
and the Public Health Agency of Canada 
(PHAC)’s Research Ethics Board. 
Analyses for this study were restricted to 
adults aged 18 to 79 years at the time of 
the MEC visit (cycle 1: n = 3726; cycle 2: 
n = 3873). We pooled data from two CHMS 
cycles in order to increase sample size and 
statistical precision of estimates.19 While 
all respondents providing urine samples 
in cycle 1 (n = 3702) were eligible for 
measurements of BPA, only a random 
subset of cycle 2 respondents (n = 1117) 
was selected for these measures, resulting 
in a combined sample of 4819 respon-
dents. We further excluded pregnant 
women (n = 37) and respondents with 
missing urinary BPA and/or creatinine 
(n = 49), yielding a final sample of 4733 
respondents.
Laboratory measurements
Single spot urine samples were collected 
as midstream urine in cycle 1 and first-
catch urine in cycle 2. Cycle 2 respondents 
were also asked to refrain from urinating 2 
hours prior to the MEC visit. The protocol 
was modified to accommodate new tests 
for infectious disease markers introduced 
in cycle 2.18 Despite these changes, uri-
nary BPA levels were similar for the two 
cycles.6 After collection and aliquoting, 
urine samples were frozen at –20°C and 
shipped on dry ice to the testing labora-
tory at the Institut national de santé pub-
lique du Québec (Quebec, Canada) for 
analysis. 
Concentrations of total BPA (free and con-
jugated) were measured using gas chro-
matography–tandem mass spectrometry 
based on previously described methods.7,20 
The limit of detection (LOD) was 0.2 µg/L 
for both cycles. Concentrations below the 
LOD (n = 436; 9%) were assigned a value 
of LOD/2 (0.1 µg/L). We categorized uri-
nary BPA concentrations into quartiles 
(< 0.7 µg/L, 0.7 to 1.2 µg/L, 1.3 to 2.4 µg/L, 
and > 2.4 µg/L) based on distribution in 
the overall study population. Additionally, 
BPA concentrations were natural-log 
transformed due to skewed distribution 
and analyzed as a continuous variable. 
Urinary creatinine was used to adjust for 
urine dilution and was measured using 
the colorimetric end-point Jaffe method.21 
Concentrations below the LOD (cycle 1: 
0.035 g/L; cycle 2: 0.050 g/L) were coded 
as missing and excluded from the analy-
ses (n = 9) as per Statistics Canada’s 
guidelines.19 To reduce potential bias asso-
ciated with systematic differences in uri-
nary creatinine concentrations across 
population characteristics (e.g. sex, age, 
race/ethnicity), we included creatinine as 
a covariate in all models instead of 
standardizing BPA concentrations for 
creatinine.22
Anthropometric measurements
Our primary outcome of interest was body 
mass index (BMI), derived from height 
and weight measured using standard pro-
cedures.23 Standing height was measured 
to the nearest 0.01 cm using a ProScale 
M150 digital stadiometer (Accurate 
Technology Inc., Fletcher, NC, USA). 
Weight was measured to the nearest 0.1 
kg using a Mettler Toledo VLC with 
Panther Plus terminal scale (Mettler Toledo 
Canada, Mississauga, ON, Canada). BMI, 
which was calculated as weight (kg) 
divided by height squared (m2), was clas-
sified into the following categories: under-
weight (< 18.5 kg/m2), normal weight 
(18.5 to 24.9 kg/m2), overweight (25.0 to 
29.9 kg/m2), obesity class I (30.0 to 
34.9  kg/m2), and obesity class II or III 
(≥ 35.0 kg/m2).4
As an indicator of abdominal fat, we also 
examined waist circumference, which was 
measured to the nearest 0.1 cm at the end 
of a normal expiration at the mid-point 
between the bottom of the rib cage and 
the top of the iliac crest.4 Central obesity 
was defined using sex-specific waist cir-
cumference cut-offs: ≥ 102 cm in males 
and ≥ 88 cm in females.4,24
Potential confounders
We identified potential confounders 
according to previous literature examining 
the BPA–obesity association in adults.11-15 
Sociodemographic variables included sex; 
age (18 to 29, 30 to 39, 40 to 49, 50 to 59, 
60 to 69, or ≥ 70 years); race/ethnicity 
(white or non-white); highest level of edu-
cation (less than secondary school degree, 
secondary school degree, or post-second-
ary degree); and household income ade-
quacy (low/lower middle, upper middle, 
or high), categorized based on annual 
household income and number of people 
living in the household. We also consid-
ered lifestyle factors, including smoking 
status (never, former, or current); alcohol 
consumption (0 to 3 times/month, 1 to 6 
times/week, or daily); and physical activ-
ity, which was assessed based on average 
daily energy expenditure during leisure-
time activities reported over the past 
3  months and categorized as active 
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(≥  3.0  kcal/kg/day), moderately active 
(1.5 to 2.9 kcal/kg/day), or inactive 
(< 1.5 kcal/kg/day).
Given that dietary intake is the primary 
source of BPA exposure and also a known 
risk factor for obesity, several dietary mea-
sures to control for potential confounding 
were developed utilizing the semi-quanti-
tative food frequency questionnaire in the 
CHMS, which asked the respondents to 
report the number of times (per day, 
week, month, or year) certain types of 
foods or drinks were consumed over the 
past year. A diet quality score was derived 
using a similar approach as the construc-
tion of a Mediterranean diet index.25 First, 
we grouped food items into seven compo-
nents (fruits; vegetables; legumes and 
nuts; cereals and grains; milk/dairy prod-
ucts; fish and seafood; and red/processed 
meat) and calculated sex-specific median 
intakes (times per day) for each. With the 
exception of red/processed meat, all com-
ponents were considered beneficial and 
assigned a value of ‘1’ when intake levels 
were above the median (red/processed 
meat intake below the median was 
assigned ‘1’). The overall diet quality 
score was determined by summing up 
values across all components and was cat-
egorized as low (0 to 3), medium (4 to 5), 
or high (6 to 7). In addition, we also 
examined consumption frequencies of 
foods or drinks that potentially contain 
BPA and/or are known to be “obesogenic” 
due to their high-energy content. These 
included sugar-sweetened beverages (e.g. 
regular/non-diet soft drinks, sport drinks, 
fruit-flavoured drinks), categorized as 
<  1  time/week, 1 to 6 times/week, or 
≥ 1 time/day; and junk food (e.g. French 
fries, regular-fat potato/tortilla/corn chips, 
ice cream), categorized as < 1 time/week, 
1 to 4 times/week, or ≥ 5 times/week.
Statistical analysis 
To account for the complex sampling 
design of the CHMS, sampling weights 
were used in all our analyses.17,18 Variance 
estimates were obtained using the boot-
strap method. Analyses were performed 
using SAS version 9.3 (SAS Institute Inc., 
Cary, NC, USA) and SUDAAN version 
11.0.1 (Research Triangle Institute, Research 
Triangle Park, NC, USA). Statistical signifi-
cance was evaluated at p < .05, and tests 
were two-sided.
Descriptive analyses were conducted to 
examine distributions of characteristics in 
the total population and by BPA quartile. 
The Rao-Scott modified chi-square test 
was used to determine whether the distri-
bution of BPA quartiles differed across cat-
egories of each characteristic. Geometric 
mean (GM) urinary BPA concentrations 
were also calculated, and differences were 
assessed using the t-test with Bonferroni-
adjusted p-values depending on the num-
ber of comparisons. 
We used multinomial logistic regression to 
examine associations between urinary 
BPA quartiles and BMI, categorized as 
under/normal weight (< 25.0 kg/m2; ref-
erence category), overweight (25.0 to 
29.9  kg/m2), or obesity (≥ 30.0  kg/m2). 
Tests for trend across quartiles were per-
formed by modelling the median of each 
BPA quartile as a continuous variable. We 
also examined natural log-transformed 
BPA concentration as a continuous vari-
able in a separate model. Furthermore, to 
assess the association between urinary 
BPA and central obesity (i.e. elevated 
waist circumference), binary logistic 
regression was performed. All basic mod-
els adjusted for sex, age (continuous years), 
TABLE 1 
Geometric mean and distribution of urinary bisphenol A concentrations across population characteristics among  
Canadian adults 18 to 79 years of age (n = 4733), 2007–2011 Canadian Health Measures Survey
Characteristics Na %b
GM 
(µg/L)
95% CI
Urinary BPA quartile, %b,c 
p-valued
1 2 3 4
All 4733 100 1.17 1.10–1.24 26.3 23.3 25.3 25.1
Sex .023
Male 2275 49.8 1.27 1.17–1.38 22.7 23.3 27.3 26.8
Female 2458 50.2 1.08 0.99–1.17 29.9 23.4 23.3 23.5
Age (years) .076
18–29 894 21.6 1.35 1.11–1.65  22.2E 24.3 25.2 28.3
30–39 899 17.4 1.34 1.19–1.50 22.5 22.1 27.4 28.1
40–49 967 21.1 1.07 0.91–1.27 28.8 21.3 22.2 27.7
50–59 602 18.8 1.18 0.98–1.44  23.6E 25.0 31.1 20.3
60–69 858 13.8 0.99 0.83–1.17 30.8 26.5 22.7 20.0
≥ 70  513  7.4 0.94 0.78–1.14 38.2 19.2 19.4 23.2
Race/ethnicity .096
White 3981 81.4 1.18 1.10–1.26 26.1 24.7 24.2 25.0
Non-white 747 18.6E 1.14 0.93–1.39 27.0 17.2 30.0 25.7
Highest level of education .681
Less than secondary school degree 656 12.2 1.11 0.94–1.32 29.0 26.5 21.2 23.2
Secondary school degree 1271 28.9 1.14 0.99–1.32 25.3 25.7 25.4 23.6
Post-secondary degree 2758 59.0 1.19 1.10–1.29 26.2 21.9 25.6 26.4
Continued on the following page
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Characteristics Na %b
GM 
(µg/L)
95% CI
Urinary BPA quartile, %b,c 
p-valued
1 2 3 4
Household income adequacy .534
Low/lower middle 1063 19.2 1.29 1.17–1.43 23.9 21.1 29.1 26.0
Upper middle 1586 31.0 1.09 0.97–1.23 29.0 23.0 25.1 23.0
High 2084 49.8 1.18 1.08–1.27 25.5 24.5 23.9 26.1
Smoking status .445
Never 2365 51.6 1.11 1.02–1.21 27.9 22.4  24.7 25.0
Former 1416 27.1 1.15 1.05–1.27 26.6 24.1 26.6 22.7
Current 952 21.3 1.34 1.14–1.58 22.0 24.7 24.9 28.5
Alcohol consumption .126
0–3 times/month 2426 50.3 1.16 1.07–1.26 27.5 21.6 24.6 26.3
1–6 times/week 1890 41.3 1.21 1.12–1.30 23.7 26.3 25.3 24.7
Daily  417  8.4 1.04 0.85–1.28 31.6 19.3 28.9 20.2
Physical activity .566
Active 1037 21.1 1.27 1.12–1.45 24.0 20.7 26.4 28.9
Moderately active 1215 24.5 1.17 1.02–1.35 26.4 23.0 26.0 24.6
Inactive 2481 54.5 1.13 1.04–1.22 27.1 24.5 24.5 23.9
Diet quality score .515
Low (0–3) 1998 43.7 1.26 1.14–1.39 25.0 21.5 26.4 27.1
Medium (4–5) 1922 40.1 1.14 1.01–1.27 25.7 24.5 26.2 23.6
High (6–7) 781 16.2 1.05 0.88–1.24 30.8 24.8  20.8E 23.6
Sugar-sweetened beverage consumption .182
< 1 time/week 2565 53.2 1.09 1.00–1.20 28.5 24.1 24.8 22.6
1–6 times/week 1419 31.1 1.26 1.16–1.38 22.9 23.3 26.0 27.8
≥ 1 time/day 748 15.8 1.26 1.09–1.45 25.5 20.8 25.4 28.4
Junk food consumption .095
< 1 time/week 1181 24.6 1.00 0.83–1.20 32.3 25.2 21.3 21.2
1–4 times/week 2739 57.5 1.21 1.13–1.31 25.0 22.4 26.5 26.1
≥ 5 times/week   811 17.9 1.29 1.11–1.51 22.0 23.7 27.0 27.3
Body mass index (kg/m2) .088
Underweight (< 18.5)    69  1.9E 0.84 0.42–1.67 ––F 49.0E ––F ––F
Normal weight (18.5–24.9) 1730 37.5 1.09 0.96–1.23 28.6 24.0 24.9 22.6
Overweight (25.0–29.9) 1737 35.2 1.21 1.08–1.36 24.9 22.2 26.7 26.2
Obesity class I (30.0–34.9) 744 16.1 1.23 1.00–1.51 28.2 21.6 20.5 29.7
Obesity class II or III (≥ 35.0)  442  9.3 1.34 1.13–1.59 18.8  22.8E 33.0  25.4E
Elevated waist circumference .823
No 2931 64.7 1.17 1.08–1.27 26.0 22.6 26.4 25.0
Yes (males: ≥ 102 cm; females: ≥ 88 cm) 1781 35.3 1.17 1.04–1.33 27.0 23.7 23.6 25.7
Abbreviations: BPA, bisphenol A; CI, confidence interval; GM, geometric mean.
Note: Percentages and GMs were weighted using sampling weights.
a Numbers may not sum up to the total (n = 4733) due to missing data for some variables.
b Percentages may not sum up to 100% due to rounding.
c Quartile 1: < 0.7 µg/L; quartile 2: 0.7–1.2 µg/L; quartile 3: 1.3–2.4 µg/L; quartile 4: > 2.4 µg/L.
d p-value from the Rao-Scott modified chi-square test comparing the distribution of BPA quartiles across categories of each characteristic. 
E Interpret with caution (coefficient of variation is between 16.6% and 33.3%).
F Data do not meet Statistics Canada’s guidelines for release due to extreme variability (coefficient of variation > 33.3%).
TABLE 1 (continued) 
Geometric mean and distribution of urinary bisphenol A concentrations across population characteristics among  
Canadian adults 18 to 79 years of age (n = 4733), 2007–2011 Canadian Health Measures Survey
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adults.24 Third, we re-ran the models 
excluding respondents with self-reported 
health professional-diagnosed chronic con-
ditions (cardiovascular disease [including 
heart attack, stroke, and any heart dis-
ease], diabetes, and/or kidney disease) 
that may be related to obesity and BPA 
exposure/excretion.28,29 Fourth, since the 
distribution of full-sample urinary BPA 
quartiles differed between males and 
females, we repeated sex-stratified models 
using sex-specific instead of full-sample 
quartiles. 
Results
Characteristics of the study population, 
including urinary BPA concentrations, are 
presented in Table 1. Overall, the GM uri-
nary BPA concentration was 1.17  µg/L 
and urinary creatinine concentration (con-
tinuous g/L). We then constructed multi-
variate models by adding individual 
variables from the list of potential con-
founders to the basic models. Variables 
were included in the final models if they 
were associated with both the exposure 
(BPA quartile; p < .20 from chi-square 
test) and the outcome (BMI or waist cir-
cumference category; entered the regres-
sion model at p < .20), or if they changed 
the sex-, age-, and creatinine-adjusted 
odds ratio (OR) for BPA by > 10%. In 
addition to sex, age, and urinary creati-
nine, all BMI and waist circumference 
models adjusted for race/ethnicity, alco-
hol consumption, and junk food con-
sumption; waist circumference models 
additionally adjusted for sugar-sweetened 
beverage consumption. We also estimated 
associations of urinary BPA (as quartiles 
or natural log-transformed continuous 
variable) with continuous measures of 
BMI and waist circumference using linear 
regression. Additionally, we stratified our 
analyses to explore potential effect modifi-
cation by sex. Statistical significance of 
multiplicative interaction terms (sex × 
BPA) was also tested.
We performed a few sensitivity analyses. 
First, since fasting status (≥ 10 or < 10 hours) 
and time of urine collection (morning, 
afternoon, or evening) may be associated 
with urinary BPA levels,26,27 we assessed 
potential confounding by these variables. 
Second, we restricted our models to 
respondents aged 18 to 64 years, as stan-
dard BMI and waist circumference classifi-
cations may not be applicable to elderly 
TABLE 2 
Associations between urinary bisphenol A and overweight and obesity (vs. under/normal weight)  
in adults 18 to 79 years of age, overall and by sex, 2007–2011 Canadian Health Measures Survey
Urinary BPA concentration
Model 1a Model 2b
N
Overweight Obesity
N
Overweight Obesity
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Overall
Quartile 1 (< 0.7 µg/L) 1345 1.00 Ref 1.00 Ref 1342 1.00 Ref 1.00 Ref
Quartile 2 (0.7–1.2 µg/L) 1010 0.94 0.59–1.50 1.05 0.71–1.54 1009 0.91 0.58–1.44 1.01 0.69–1.48
Quartile 3 (1.3–2.4 µg/L) 1210 1.10 0.73–1.67 1.23 0.83–1.81 1208 1.09 0.70–1.70 1.26 0.85–1.87
Quartile 4 (> 2.4 µg/L) 1157 1.18 0.76–1.83 1.56 1.02–2.38 1156 1.14 0.73–1.77 1.54 1.002–2.37
p-trendc .322 .036 .394 .041
Log BPA (continuous) 4722 1.05 0.90–1.22 1.15 1.01–1.31 4715 1.03 0.89–1.20 1.15 1.004–1.31
Males
Quartile 1 (< 0.7 µg/L) 537 1.00 Ref 1.00 Ref 537 1.00 Ref 1.00 Ref
Quartile 2 (0.7–1.2 µg/L) 483 1.14 0.57–2.27 1.26 0.64–2.49 483 1.05 0.52–1.14 1.08 0.52–2.25
Quartile 3 (1.3–2.4 µg/L) 635 1.44 0.72–2.90 1.42 0.64–3.17 633 1.41 0.69–2.92 1.45 0.60–3.49
Quartile 4 (> 2.4 µg/L) 618 1.51 0.81–2.82 1.77 0.78–4.01 618 1.43 0.74–2.74 1.60 0.67–3.80
p-trendc .208 .193 .248 .266
Log BPA (continuous) 2273 1.17 0.95–1.45 1.19 0.94–1.52 2271 1.16 0.93–1.44 1.17 0.91–1.51
Females
Quartile 1 (< 0.7 µg/L) 808 1.00 Ref 1.00 Ref 805 1.00 Ref 1.00 Ref
Quartile 2 (0.7–1.2 µg/L) 527 0.83 0.42–1.65 0.90 0.49–1.66 526 0.84 0.42–1.66 0.93 0.52–1.68
Quartile 3 (1.3–2.4 µg/L) 575 0.86 0.45–1.64 1.12 0.56–2.23 575 0.86 0.44–1.67 1.16 0.60–2.27
Quartile 4 (> 2.4 µg/L) 539 0.95 0.49–1.85 1.41 0.72–2.75 538 0.93 0.46–1.86 1.47 0.77–2.81
p-trendc .960 .211 .973 .169
Log BPA (continuous) 2449 0.92 0.77–1.11 1.12 0.92–1.36 2444 0.91 0.75–1.10 1.12 0.93–1.36
Abbreviations: BPA, bisphenol A; CI, confidence interval; OR, odds ratio; Ref, reference category. 
a Adjusted for sex (overall model only), age, and urinary creatinine concentration. 
b Adjusted for Model 1 covariates plus race/ethnicity, alcohol consumption, and junk food consumption. 
c p-value for test of trend calculated by modelling the median of each BPA quartile as a continuous variable. 
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(95% confidence interval [CI]: 1.10–1.24). 
GMs decreased with age and were signifi-
cantly higher among males and those who 
consumed junk food ≥ 5 times/week (all 
p < .05; data not shown). With the excep-
tion of sex (p = .023), the distribution of 
BPA quartiles did not differ by any of the 
characteristics. 
As shown in Table 1, 60% of Canadian 
adults were overweight (35%) or obese 
(25%), and 35% had an elevated waist 
circumference (i.e. centrally obese). GM 
urinary BPA concentrations increased 
with BMI, from 0.84 µg/L (95% CI: 0.42–
1.67) and 1.09 µg/L (95% CI: 0.96–1.23) 
among underweight and normal weight 
individuals, respectively, to 1.34 µg/L 
(95% CI: 1.13–1.59) among those in the 
class II/III obese categories (p-trend = 0.06). 
BPA concentrations did not differ by waist 
circumference category.
Table 2 presents associations of urinary 
BPA with BMI-defined overweight and 
obesity, overall and by sex. In the overall 
model adjusted for sex, age, and urinary 
creatinine (model 1), respondents in the 
highest BPA quartile had a significantly 
higher odds of being obese (vs. under/
normal weight) compared to those in the 
lowest quartile (OR = 1.56, 95% CI: 1.02–
2.38), with an increasing trend across 
increasing quartiles (p-trend  =  .036). 
Results remained largely unchanged fol-
lowing additional adjustment for potential 
confounders (model 2) (OR [quartile 4 vs. 
1] = 1.54, 95% CI: 1.002–2.37; p-trend = 
.041). Similarly, natural log-transformed 
BPA (continuous) was positively associ-
ated with obesity (OR = 1.15, 95% CI: 
1.004–1.31). For the overweight category, 
associations were generally positive but 
nonsignificant, with an OR of 1.14 (95% 
CI: 0.73–1.77) in the highest (vs. lowest) 
BPA quartile. When results were exam-
ined by sex, associations between urinary 
BPA and both overweight and obesity did 
not reach statistical significance in either 
sex. Although there was no evidence of a 
significant sex × BPA interaction (p > .05; 
data not shown), we observed stronger 
positive associations in males than 
females for both overweight (OR [quartile 
4 vs. 1] = 1.43 vs. 0.93) and obesity (OR 
[quartile 4 vs. 1] = 1.60 vs. 1.47).
We did not find significant associations 
between urinary BPA and central obesity, 
overall (OR [quartile 4 vs. 1] = 1.16, 95% 
CI: 0.81–1.66; p-trend = .463) or by sex 
(Table 3). Sex-stratified models suggested 
a stronger association in males than 
females (OR [quartile 4 vs. 1] = 1.28 vs. 
1.03), although a statistically significant 
interaction was not found (p > .05; data 
not shown). Additional adjustment for 
height in the models to control for overall 
stature did not alter the results (data not 
shown).
Figure 1 presents associations of urinary 
BPA quartile with continuous measures of 
BMI and waist circumference. Respond-
ents in the third and fourth BPA quartiles 
had significantly greater BMI (1.03 kg/m2, 
95% CI: 0.30–1.76; and 1.06 kg/m2, 95% 
CI: 0.18–1.93, respectively) compared to 
those in the first quartile. A similar pat-
tern was observed for waist circumfer-
ence, although statistical significance was 
reached in the third (2.42 cm, 95% CI: 
0.46–4.39) but not the fourth (2.73 cm, 
95% CI: –0.14 to 5.60) quartile. Further-
more, each natural-log increase in urinary 
BPA concentration was associated with a 
0.33 kg/m2 (95% CI: 0.10–0.57) increase 
in BMI and a 1.00 cm (95% CI: 0.34–1.65) 
increase in waist circumference (Table 4), 
with slightly stronger associations in 
females (p for interaction > .05; data not 
shown).
In our sensitivity analyses (data available 
by request), inclusion of fasting status or 
time of urine collection did not change 
effect estimates by > 10% in any of the 
models, indicating that these variables did 
not confound the associations observed. 
Next, analyses restricted to adults aged 18 
to 64 years yielded similar results, with 
TABLE 3 
Associations between urinary bisphenol A and central obesitya in adults 18 to 79 years of 
age, overall and by sex, 2007–2011 Canadian Health Measures Survey
Urinary BPA concentration
Model 1b Model 2c
N OR 95% CI N OR 95% CI
Overall
Quartile 1 (< 0.7 µg/L) 1342 1.00 Ref 1339 1.00 Ref
Quartile 2 (0.7–1.2 µg/L) 1003 1.12 0.76–1.67 1001 1.12 0.75–1.65
Quartile 3 (1.3–2.4 µg/L) 1211 0.96 0.64–1.45 1209 0.99 0.67–1.46
Quartile 4 (> 2.4 µg/L) 1156 1.16 0.81–1.65 1155 1.16 0.81–1.66
p-trendd .470 .463
Log BPA (continuous) 4712 1.06 0.96–1.16 4704 1.05 0.96–1.16
Males
Quartile 1 (< 0.7 µg/L) 537 1.00 Ref 537 1.00 Ref
Quartile 2 (0.7–1.2 µg/L) 479 1.41 0.88–2.26 478 1.27 0.80–2.02
Quartile 3 (1.3–2.4 µg/L) 636 1.31 0.86–1.99 634 1.32 0.89–1.98
Quartile 4 (> 2.4 µg/L) 618 1.41 0.78–2.55 618 1.28 0.72– 2.27
p-trendd .434 .616
Log BPA (continuous) 2270 1.08 0.92–1.28 2267 1.07 0.91–1.26
Females
Quartile 1 (< 0.7 µg/L) 805 1.00 Ref 802 1.00 Ref
Quartile 2 (0.7–1.2 µg/L) 524 0.95 0.55–1.65 523 1.01 0.57–1.77
Quartile 3 (1.3–2.4 µg/L) 575 0.76 0.43–1.36 575 0.80 0.45–1.44
Quartile 4 (> 2.4 µg/L) 538 1.00 0.60–1.66 537 1.03 0.64–1.65
p-trendd .902 .864
Log BPA (continuous) 2442 1.03 0.87–1.18 2437 1.03 0.90–1.18
Abbreviations: BPA, bisphenol A; CI, confidence interval; OR, odds ratio; Ref, reference category. 
a Waist circumference ≥ 102 cm in males and ≥ 88 cm in females.
b Adjusted for sex (overall model only), age, and urinary creatinine concentration. 
c Adjusted for Model 1 covariates plus race/ethnicity, alcohol consumption, junk food consumption, and sugar-sweetened bever-
age consumption.
d p-value for test of trend calculated by modelling the median of each BPA quartile as a continuous variable. 
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slightly stronger associations for obesity 
(OR [quartile 4 vs. 1] = 1.64, 95% CI: 
1.01–2.66; p-trend = .018), as compared 
to analyses conducted on the full sample. 
Similarly, when we restricted our analyses 
to respondents without specific chronic 
conditions, results did not change appre-
ciably. Finally, when sex-stratified analy-
ses were repeated using sex-specific 
instead of full-sample quartiles, effect esti-
mates changed slightly (e.g. OR for obe-
sity was attenuated in both sexes for 
quartile 4 vs .1) but were generally in the 
same direction, with stronger positive 
associations consistently observed in males. 
Discussion
Using data from the CHMS, our study pro-
vides, for the first time, an examination of 
associations between BPA and indicators 
of obesity in the general Canadian adult 
population. We found that urinary BPA 
was positively associated with BMI-
defined general obesity in a dose-depen-
dent manner and that this association 
persisted after controlling for potential 
confounders, including diet-related fac-
tors. These findings are consistent with 
other large-scale cross-sectional studies of 
adults in the USA11,12 and China,13 as well 
as with studies in children.30-33 Effect sizes 
in our study were slightly lower than 
those reported using the US National 
Health and Nutrition Examination Survey11 
(OR [quartile 4 vs. 1] = 1.76) and were 
more similar with the study in Chinese 
adults13 (OR [quartile 4 vs. 1] = 1.50). A 
possible explanation for the weaker asso-
ciations, compared to US results, may be 
related to the substantially lower BPA con-
centrations in our study and the Chinese 
study. In addition, while our results dem-
onstrated increasing odds of obesity 
across increasing urinary BPA quartiles, 
some studies reported a potential thresh-
old or non-monotonic effect.11,15,32 Although 
non-monotonic associations have been 
commonly observed for BPA and other 
endocrine disruptors in toxicological stud-
ies,34 ubiquitous low-level exposures to 
BPA in human populations present a chal-
lenge for assessing and interpreting dose-
response relationships.35
Consistent with previous studies,11,13,14 our 
study also provides evidence for positive 
associations between urinary BPA and 
continuous BMI and waist circumference 
measures. However, unlike studies in the 
USA11,12 and Asia,13,14 we did not find an 
association between urinary BPA and cen-
tral obesity defined using waist circumfer-
ence cut-offs. Although we used the same 
cut-offs as the US studies, differences in 
racial/ethnic makeup between the popula-
tions may have contributed to the discrep-
ant findings.36 Furthermore, it has been 
shown that urinary BPA concentration dif-
fered by race/ethnicity and was signifi-
cantly higher among black compared to 
white Americans.27 However, owing to 
small sample sizes of individual ethnic 
groups within our study population, we 
could not further control for race/ethnic-
ity or examine race/ethnicity-specific 
associations. 
Several biological mechanisms have been 
proposed to explain the association 
between BPA and obesity, although the 
exact mode of action remains unclear. For 
example, BPA has been shown to promote 
adipocyte differentiation and fat accumu-
lation,9 as well as bind to estrogen recep-
tors on adipocytes and inhibit the release 
of the hormone adiponectin.37 While most 
animal studies focused on in utero expo-
sure, Miyawaki et al.10 showed that BPA 
exposure during both perinatal and post-
natal periods led to weight gain in mice. 
Additionally, long-term exposure to BPA 
in adult mice was shown to increase 
a dipose tissue mass and induce insulin 
resistance, hyperglycemia, and hypercho-
lesterolemia,38 suggesting the role of BPA 
in the development of obesity and cardio-
metabolic dysfunction. Similarly, epidemio-
logical studies provide growing evidence 
that, in addition to obesity, exposure to 
BPA may be associated with increased risk 
of diabetes and cardiovascular disorders.39
FIGURE 1 
Mean difference in (A) body mass index and (B) waist circumference  
across urinary bisphenol A quartiles (vs. quartile 1) in adults 18 to 79 years  
of age, overall and by sex, 2007–2011 Canadian Health Measures Survey
Abbreviations: BMI, body mass index; BPA, bisphenol A. 
Notes: Quartile 1: < 0.7 µg/L; quartile 2: 0.7–1.2 µg/L; quartile 3: 1.3–2.4 µg/L; quartile 4: > 2.4 µg/L.
All models adjusted for sex (overall models only), age, urinary creatinine concentration, race/ethnicity, alcohol consumption, and 
junk food consumption. Models for waist circumference additionally adjusted for sugar-sweetened beverage consumption. Error 
bars represent 95% confidence intervals. 
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Like most epidemiological studies, we did 
not find evidence of effect modification by 
sex in the association between urinary 
BPA and obesity. Sex differences in the 
BPA–obesity association have been impli-
cated in animal studies,16,40 possibly relat-
ing to differences in BPA metabolism41 and 
estrogen receptor expression,42 as well as 
sex-specific effects of BPA on dietary 
intake and energy expenditure.43 Given 
the biological plausibility, more research 
is needed to delineate potential sex differ-
ences in BPA-induced health outcomes.
Strengths and limitations
This is the first Canadian study to exam-
ine associations between BPA and indica-
tors of obesity in adults. Strengths of our 
study include the population-based design, 
large sample size, direct anthropometric 
measurements, high-quality urinary BPA 
assays, and assessment of multiple poten-
tial confounders, including several dietary 
factors. This is important as recent sys-
tematic reviews have pointed out the lack 
of adjustment for diet, especially pro-
cessed food consumption, as a major limi-
tation of studies investigating associations 
between BPA and health outcomes.26,35,39
This study has several limitations. First, 
due to the cross-sectional nature of CHMS 
data, temporal relationships could not be 
established. It is possible that obese indi-
viduals store, metabolize, and/or excrete 
BPA differently from non-obese individu-
als, leading to higher BPA levels in their 
TABLE 4 
Associations between log-transformed urinary bisphenol A and continuous measures of 
body mass index and waist circumference in adults 18 to 79 years of age, overall and by sex, 
2007–2011 Canadian Health Measures Survey
Body mass index (kg/m2)a Waist circumference (cm)b
N βc 95% CI N βc 95% CI
Overall
Log BPA (continuous) 4715 0.33 0.10 to 0.57 4704 1.00 0.34 to 1.65
Males
Log BPA (continuous) 2271 0.28 –0.04 to 0.59 2267 0.72 –0.22 to 1.67
Females
Log BPA (continuous) 2444 0.38 0.73 to 2.28 2437 1.16 0.39 to 1.92
Abbreviations: BPA, bisphenol A; CI, confidence interval. 
a Adjusted for sex (overall model only), age, urinary creatinine concentration, race/ethnicity, alcohol consumption, and junk 
food consumption. 
b Adjusted for sex (overall model only), age, urinary creatinine concentration, race/ethnicity, alcohol consumption, junk food 
consumption, and sugar-sweetened beverage consumption.
c Mean change in body mass index (kg/m2) or waist circumference (cm) per natural-log unit increase in urinary BPA 
concentration. 
urine.44,45 Nonetheless, a recent prospec-
tive cohort study of women showed that 
higher urinary BPA concentration at base-
line was associated with greater weight 
gain during a 10-year follow-up,46 although 
additional longitudinal studies in both 
sexes are warranted. Second, single spot 
urine measures may not be representative 
of long-term exposure to BPA. Consid-
erable within-person variability has been 
shown in urinary BPA measured through-
out the day and week47 and over a period 
of 1 to 3 years,48 likely relating to varia-
tions in dietary intake. However, our sen-
sitivity analyses showed that time of urine 
collection and fasting status did not con-
found the associations observed. More-
over, a recent panel study collected 
repeated measures of urinary BPA and 
BMI over a 3-year period and found sig-
nificant positive associations with over-
weight in elderly adults regardless of 
whether single or average BPA measures 
were analyzed.15
Conclusion
In a nationally representative sample of 
Canadian adults, we showed that urinary 
BPA was positively associated with gen-
eral obesity, as well as with continuous 
BMI and waist circumference. While the 
imbalance between energy intake and 
energy expenditure remains a major con-
tributor to obesity, health and economic 
consequences of obesity attributable to 
BPA exposure should not be ignored.49 
Furthermore, although BPA is not currently 
prohibited in Canada, except in baby bot-
tles and cosmetic products, it has been 
recommended to limit BPA exposure from 
food packaging given potential effects on 
health outcomes such as obesity.6 This 
underscores the need to further explore 
the role of BPA as a potential environmen-
tal obesogen. Future studies should aim to 
collect prospective data with repeated 
measures over extended time periods in 
order to improve exposure classification 
and address the temporal relationship 
between BPA and obesity. 
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